Cholesterol Management
Introduction
- Cholesterol management involves reducing LDL-C levels to prevent cardiovascular events, with various treatment regimens and target levels recommended by different guideline societies [@A1@, 1]
Treatment Regimens
- The European Society of Cardiology recommends a treatment regimen of rosuvastatin 10 mg with ezetimibe 10 mg once daily as first-line combination therapy for patients with high cholesterol who require significant LDL-C reduction, with potential dose adjustment to rosuvastatin 20 mg with ezetimibe 10 mg for those not achieving target LDL-C levels 1
- Combination therapy with rosuvastatin and ezetimibe is significantly more effective than doubling the rosuvastatin dose alone in reducing LDL-C levels, and is better tolerated with fewer side effects 2
- The American Heart Association recommends adding ezetimibe to statin therapy, resulting in a significant 2% absolute reduction in the composite of cardiovascular death, major coronary events, or stroke compared with statin monotherapy, with high-risk patients showing the greatest benefit 3
Target LDL-C Levels
- The European Society of Cardiology recommends target LDL-C levels of <1.4 mmol/L (55 mg/dL) and ≥50% reduction from baseline for very high-risk patients (established CVD) 1
- The European Society of Cardiology recommends target LDL-C levels of <1.0 mmol/L (40 mg/dL) for patients with recurrent atherothrombotic events within 2 years 1
- The Canadian Cardiovascular Society guidelines recommend a target LDL-C level of <1.8 mmol/L (70 mg/dL) or a ≥50% reduction from baseline for patients starting rosuvastatin 10 mg daily with an initial LDL of 5.78 mmol/L 4, 5
- The following target LDL-C levels are recommended for different patient categories:
| Patient Category | Target LDL-C Level |
|---|---|
| High-risk patients | <1.8 mmol/L (70 mg/dL) |
| Very high-risk patients | <1.4 mmol/L (55 mg/dL) |
| General patients | <1.8 mmol/L (70 mg/dL) or ≥50% reduction from baseline |
- If the absolute target LDL-C level cannot be achieved, a minimum of 50% reduction from baseline LDL-C is an acceptable alternative target 5
Medication Administration
- Fixed-dose combination of ezetimibe and rosuvastatin improves medication adherence compared to separate pills 2
- The European Society of Cardiology does not recommend the use of rosuvastatin and ezetimibe during pregnancy or breastfeeding 1
- For patients with severe renal impairment (CrCl <30 mL/min), the maximum dose of rosuvastatin should not exceed 10 mg daily 4
- Rosuvastatin is generally well-tolerated at 10 mg daily, but patients should be monitored for muscle symptoms and liver function abnormalities 4
Clinical Trial Evidence
- The I-ROSETTE trial demonstrated that all fixed-dose combinations of ezetimibe/rosuvastatin significantly improved lipid profiles compared with rosuvastatin monotherapy, with all combination groups achieving >50% reduction in LDL-C from baseline 2
- The addition of ezetimibe to statin therapy may be particularly beneficial for patients who have previously experienced statin-related side effects at higher doses, with a similar safety profile to rosuvastatin monotherapy 2
- Very low LDL-C levels (<30 mg/dL) appear to be safe based on clinical trials, with no significant increase in adverse events 6
- Lipid profile should be checked 4-12 weeks after initiating therapy to assess response 7